Intuitive Surgical, Inc.

Intuitive Surgical, Inc. (ISRG) Market Cap

Intuitive Surgical, Inc. has a market capitalization of —.

No quote data available.

CEO: David J. Rosa

Sector: Healthcare

Industry: Medical - Instruments & Supplies

IPO Date: 2000-06-16

Website: https://www.intuitive.com

Intuitive Surgical, Inc. (ISRG) - Company Information

Market Cap: -|Sector: Healthcare

Company Profile

Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach. Expanding beyond surgical applications, the company also provides the Ion endoluminal system, designed for diagnostic interventions like minimally invasive lung biopsies. Complementing its primary systems, Intuitive Surgical supplies a comprehensive array of instruments, including stapling tools, energy devices, and essential core components. Furthermore, it offers structured training programs to ensure proficient use of its technology, alongside extensive customer support services encompassing installation, repairs, and ongoing maintenance. The firm also integrates digital capabilities to deliver unified, connected solutions that optimize hospital performance through actionable insights. Established in 1995, Intuitive Surgical maintains its corporate headquarters in Sunnyvale, California.

Analyst Sentiment

73%
Strong Buy

From 36 Active Polls

1Y Forecast: $491.15

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$357

Median

$494

High Bound

$651

Average

$491

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$491.15
▲ +39.01% Upside
Low Target
$357.44
1% Risk
Median Target
$493.50
40% Mid
High Target
$651.00
84% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

valuation & financial ratiosdetailed financials

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 INTUITIVE SURGICAL INC (ISRG) — Investment Overview

🧩 Business Model Overview

Intuitive Surgical operates a platform-based model in surgical robotics. The company sells a capital equipment system (the robotic surgical platform) that enables surgeons to perform minimally invasive procedures with instrumented precision. Revenue is then reinforced by a tightly coupled ecosystem of consumable instruments (instruments, staplers, and related surgical accessories) plus installation, training, and ongoing service support. This structure creates an “installed base” dynamic: hospitals justify the initial platform purchase because the platform’s instruments and workflow become operationally embedded, and the provider continues to generate value as patient volumes and procedure mix expand.

💰 Revenue Streams & Monetisation Model

Monetisation is dominated by recurring and high-frequency consumables tied to each procedure. The main revenue components typically include:

  • System sales (capital platform): less frequent, driven by new installations, replacement cycles, and facility expansion.
  • Instrument and accessory sales (procedure-linked consumables): the primary volume driver; these products are used repeatedly across surgeries, supporting a recurring revenue profile.
  • Service and support: multi-year service contracts and service-related revenue that stabilizes cash flows.
  • Training and other ancillary services: supportive, but typically smaller relative to instruments/service.

Margin profile tends to reflect (1) the degree of install-base penetration and utilization, (2) mix shift toward higher-value instruments and accessories, and (3) service attachment rates. The installed base also enables better predictability than a pure capital equipment model because a significant portion of demand correlates with procedure volumes rather than new system placements alone.

🧠 Competitive Advantages & Market Positioning

Core moat: High switching costs and an integrated clinical workflow ecosystem. Once a hospital standardizes on a robotic platform, adoption of a different system can require retraining, workflow changes, different instrument sets, and operational adjustments across the surgical team. This creates practical friction that reduces near-term switching likelihood. Intuitive’s installed base, long-running procedure experience, and breadth of instrument compatibility reinforce this stickiness.

Industry focus vs. competitors: Intuitive Surgical is primarily focused on maximizing platform utilization through a mature ecosystem of instruments, services, and clinical adoption programs. Competitors generally attempt to differentiate through platform design, instrument architecture, and cost structure. Key competitor benchmarks include:

  • Medtronic (Hugo system): a credible robotics entrant using a different platform approach; competition centers on ease of adoption and clinical workflow considerations.
  • CMR Surgical (Versius system): targets scalability and potentially lower total costs of ownership; competition emphasizes platform deployment and modularity.
  • Surgical robotics startups and emerging entrants (varied approaches across instrument design and clinical focus): often focus on select procedures and incremental adoption.

Despite these efforts, Intuitive’s competitive positioning benefits from a larger installed base and a deeply established instrument/service ecosystem that ties physician training, operating room workflows, and procurement cycles to the platform. This is the primary reason competitors face difficulty displacing share quickly—even when alternative systems demonstrate technical capabilities.

🚀 Multi-Year Growth Drivers

  • Secular shift toward minimally invasive surgery: robotics supports surgeon ergonomics and procedural precision, enabling continued substitution of open and some laparoscopic approaches where clinically appropriate.
  • Procedure expansion within the installed base: continued adoption across new specialties and indications can increase instrument consumption per patient and improve platform utilization.
  • International and facility penetration: growth opportunities exist as more hospitals add robotics capability and as training and service capacity scale to support broader geographic adoption.
  • Demand durability driven by outcomes and operating efficiency: where payer and provider incentives align with shorter recovery profiles and resource efficiency, procedure volumes can expand sustainably.
  • Service and consumables attach depth: once installed, instrument and service attachment become key levers; utilization improvements tend to compound over time.

⚠ Risk Factors to Monitor

  • Regulatory and clinical acceptance risk: new indications require clinical evidence and regulatory clearance; safety events or slower-than-expected adoption can affect utilization.
  • Reimbursement and payer pressure: procedure reimbursement dynamics can influence hospital economics and the pace of adoption or utilization.
  • Competitive platform displacement: emerging robotics platforms may offer differentiated cost structures, broader instrument compatibility, or improved workflow, potentially pressuring share and pricing.
  • Pricing and instrument mix scrutiny: dependence on consumable demand exposes margins to changes in instrument pricing, hospital contracting leverage, and policy scrutiny.
  • Concentration of technology and supply chain: platform-dependent instruments and service components create execution risk; manufacturing quality and supply stability are critical.
  • Cybersecurity and operational continuity: connected and software-dependent systems raise cybersecurity and reliability considerations for hospitals and regulators.

📊 Valuation & Market View

Market valuation for surgical robotics generally reflects a blend of platform adoption and the durability of recurring consumables/service revenue. Investors often anchor on metrics such as EV/Revenue or EV/EBITDA for growth visibility, but the key drivers that typically move expectations include:

  • Installed base growth and new-system conversion strength.
  • Instrument and service attachment translating into recurring revenue quality.
  • Utilization trends driven by procedure volumes and breadth of indications.
  • Gross margin durability, particularly through instrument mix and service economics.

In this sector, the market tends to reward consistent evidence that consumables demand scales with the installed base while limiting competitive erosion in pricing and share.

🔍 Investment Takeaway

Intuitive Surgical’s long-term thesis rests on a structural advantage: a robotics platform embedded in hospital surgical workflows, reinforced by high switching costs and a mature, procedure-linked ecosystem of instruments and service. While competition from other robotics vendors can influence adoption pace and pricing dynamics, Intuitive’s installed base economics and integrated ecosystem create meaningful barriers to rapid displacement. The investment case improves when procedure volumes expand within the installed base and when service/consumables remain durable relative to platform churn.


⚠ AI-generated — informational only. Validate using filings before investing.

Related Companies in Healthcare

SOLVENTUM CORP (SOLV)

Healthcare

$14.80B

Mkt Cap

INSULET CORP (PODD)

Healthcare

$11.45B

Mkt Cap

GE HEALTHCARE TECHNOLOGIES INC (GEHC)

Healthcare

$30.72B

Mkt Cap

MOLINA HEALTHCARE INC (MOH)

Healthcare

$10.21B

Mkt Cap

BIO TECHNE CORP (TECH)

Healthcare

$11.29B

Mkt Cap

MODERNA INC (MRNA)

Healthcare

$21.75B

Mkt Cap

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-06-30

"ISRG (Q2 2026, ended 2026-06-30) reported Revenue of $2.892B and Net Income of $818M. Diluted EPS was $2.35. On a YoY basis, Revenue rose from $2.440B (Q2 2025) to $2.892B (+18.6%), while Net Income increased from $658M to $818M (+24.2%). On a QoQ basis, Revenue grew from $2.771B (Q1 2026) to $2.892B (+4.3%); Net Income was roughly flat/slightly down from $822M (+(0.4)%). Profitability remained strong. Gross margin improved to 67.8% (up from 66.1% in Q1 2026 and up from 66.3% in Q2 2025). Net margin ticked up YoY to 28.3% (from 27.0%) but dipped slightly QoQ (29.6% in Q1 2026). Operating income margin also edged up YoY (33.6% vs. ~30.5% in Q2 2025). Cash flow quality was excellent: Operating Cash Flow was $1.061B and Free Cash Flow was $948M. The company generated substantial cash while funding continued shareholder return via buybacks ($320M repurchased in Q2 2026) and no dividends. Balance sheet resilience is notable for a non-bank: Total assets were $20.9B and total stockholders’ equity was $18.2B. Net cash remains large (net debt of about -$8.6B), with no debt shown. Total shareholder returns: the provided marketPerformance shows the stock down -2.5% over 1Y, so momentum did not boost the score (dividend yield is 0%)."

Revenue Growth

Good

YoY Revenue +18.6% ($2.440B to $2.892B). QoQ Revenue +4.3% ($2.771B to $2.892B), indicating sustained acceleration but some deceleration vs. earlier quarters.

Profitability

Strong

Gross margin expanded to 67.8% (from 66.1% QoQ and 66.3% YoY). Net margin improved YoY to 28.3% (from 27.0%) while slipping slightly QoQ (29.6% in Q1). EPS was up vs. Q2 2025 ($2.35 vs. $1.81).

Cash Flow Quality

Good

Q2 2026 Operating Cash Flow $1.061B and Free Cash Flow $948M. Buybacks continued ($320M) and dividends were 0; financing appears flexible given strong earnings-to-cash conversion.

Leverage & Balance Sheet

Strong

Net cash position strengthened materially (net debt about -$8.6B in Q2 2026 vs. -$2.0B in Q1 2026). Total assets rose to $20.9B with equity at $18.2B, indicating strong balance-sheet resilience.

Shareholder Returns

Positive

Cash deployment via buybacks ($320M repurchased) supports capital appreciation. However, the stock’s 1Y change is -2.5% and dividend yield is 0%, limiting total return.

Analyst Sentiment & Valuation

Neutral

Using the provided price ($469.21) vs. consensus target ($525): moderate upside implied (~+12%). Valuation ratios are rich (e.g., P/E ~42.9 and P/FCF very elevated), so expectation of sustained growth is priced in.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

RevenueEarningsP/E RatioSharesDebtMargin %

Fundamentals Overview

Loading fundamentals overview...

ISRG delivered strong Q2 momentum: revenue +19% to $2.89B and non-GAAP EPS +28% to $2.80, supported by da Vinci +15% and ION +36% procedure growth and solid utilization (+3% da Vinci, +11% ION). Non-GAAP gross margin expanded to 70% (+210 bps YoY), but management tied part of the improvement to a $36M pretax IEPA tariff refund; ex-tariff, gross margin would have been 68.7%. The core risk theme is timing: US growth moderated (da Vinci +12%) with management citing ACA enhanced premium subsidy expirations and ongoing GLP-1 impacts on bariatrics, plus continued softness in deferrable benign procedures. Internationally, China remains the principal headwind (tender weakness, domestic competition, policy pricing pressure; da Vinci 5 not cleared in Mainland). Outlook is maintained: 2026 da Vinci procedure growth 13.5%-15.5% and gross margin 68%-69%, with operating expense growth 11%-13%, while extended-use instruments and da Vinci 5 platform updates aim to unlock incremental adoption in cost-sensitive markets.

AI IconGrowth Catalysts

  • Da Vinci procedure growth +15% overall; US da Vinci +12% led by general surgery and after-hours procedures (+26%).
  • ION procedure growth +36% to 48k; cumulatively exceeds 400k procedures; installed base +21% (ION systems).
  • da Vinci SP momentum: SP procedures +61%; SP stapler used in ~60% of eligible cases in the US (up from <40% last quarter); expected Japan availability in Q3.
  • Da Vinci 5 platform rollout: 246 da Vinci 5 placements; 114 dual consoles; US da Vinci systems placed +24% YoY.
  • My Intuitive Plus renewals: first wave cohort small, but no customers opted out; early evidence of stickiness across telepresence/simulation/AI insights.
  • Extended-use ENDORIST program: May initiative targeting increased uses on a subset of instruments to reduce benign-procedure customer cost per use in 1H27.

Business Development

  • FDA 510(k) submissions for da Vinci 5 platform updates tied to more usability/efficiency features; specific cadence of >100 planned da Vinci 5 phase updates (first phase rolled out in Q2).
  • India: da Vinci 5 clearance received this week; plans to bring latest generation platform to Indian customers.
  • Japan: new robotic reimbursement policies effective June 1 (supports additional procedures and incentives for higher utilization programs).
  • China: engaging with provincial governments on charge code policy; progressing through green channel process for SP and da Vinci 5.
  • Force-feedback evidence cited (AUA/JUrology abstract) supporting faster return of bowel function; management referenced adoption as an I&A/clinical catalyst.

AI IconFinancial Highlights

  • Revenue +19% YoY to $2.89B; constant-currency revenue +18%.
  • Non-GAAP EPS +28% YoY to $2.80.
  • Non-GAAP operating margin: 42%.
  • Non-GAAP gross margin: 70% vs 67.9% in Q2 last year (+210 bps). Excluding $36M pretax IEPA tariff refund, non-GAAP gross margin would have been 68.7% (tariff-related impact called out).
  • Recurring revenue +19% to $2.47B; 85% of total revenue.
  • System utilization: da Vinci utilization +3% and ION utilization +11% (recurring utilization growth supported I&A).
  • Da Vinci I&A revenue per procedure: ~$1.83k vs ~$1.8k last year; drivers included higher SP/da Vinci 5 mix offset by ordering/procedure mix (more cholecystectomy; lower bariatric).
  • US macro/policy headwind: modest adverse impact on US da Vinci procedure growth attributed to ACA enhanced premium subsidy expirations; also benign/deferred procedure moderation since Q1.
  • Tax: non-GAAP effective tax rate 22.6% (consistent with expectations); full-year non-GAAP tax rate guided 22%-23%.

AI IconCapital Funding

  • Ended Q2 with $8.6B cash and investments (up from $8.0B last quarter).
  • Q2 stock repurchases: $379M at average price $439/share.
  • Q2 capital expenditures: $112M.
  • H1 free cash flow: $1.8B (+71% YoY).

AI IconStrategy & Ops

  • Rolled out first phase of >100 planned da Vinci 5 updates in Q2 (telepresence, simulation-based training, care team workflow).
  • Planned platform enhancements: submitted multiple da Vinci 5 innovations for FDA 510(k) clearance leveraging those updates.
  • Instruments strategy: extended-use ENDORIST program (benefit targeted to reduce costs in a set of benign procedures) with 1H27 expected increase in uses on a subset of instruments; excludes stapling/energy force-feedback instruments from the program.
  • Supply/value-access segmentation: increased adoption of da Vinci XiR in cost-constrained countries and in US ASCs; positioned as expanding access while maintaining Gen 4 ecosystem value.
  • Manufacturing capacity: added 215 employees in Q2 (about half in manufacturing) to support demand.

AI IconMarket Outlook

  • Updated 2026 da Vinci procedure growth forecast maintained: 13.5% to 15.5%, expecting closer to midpoint (management referenced drivers and risks including US ACA/patient behavior, China tenders/competitive intensity, and Europe capital pressure tied to macroeconomic impact).
  • Non-GAAP gross profit margin forecast updated to 68%-69% of revenue (vs prior call range 67.5%-68.5%); stated context includes ~100 bps gross margin impact from tariffs previously.
  • Non-GAAP operating expense growth forecast: 11%-13%.
  • Non-GAAP income tax rate forecast: 22%-23% of pretax income.
  • Other income forecast: $315M to $335M.

AI IconRisks & Headwinds

  • US: deferred procedures/case timing impacted by ACA enhanced premium subsidy expirations; inquiry also noted belief of patient/coverage dynamics altering when patients seek care.
  • US benign/procedure mix: GLP-1 usage impact on da Vinci bariatric cases (declining high single digits during the quarter).
  • China: lower tender activity, increased domestic robotic competition, and policy-driven pricing pressure; da Vinci 5 not cleared in Mainland China (first Hong Kong da Vinci 5 placement only).
  • Europe: some markets stressed by government budgets; management flagged variability across geographies.
  • Japan: prior government funding/capital challenges persist, but June 1 reimbursement changes were described as directionally positive.

Q&A: Analyst Interest

  • ACA and deferred-procedure timing: Management said they rely on direct customer procedure-trend feedback plus comparing deferrable versus less-deferrable procedure categories. They noted Q2 US da Vinci procedure growth at 12% vs 14% in Q1 and attributed part of the delta to ACA, but also normal volatility.
  • Extended-use/EUP economics and patient/capex adoption: Management would not quantify yet. They framed the initiative as multi-year engineering work to extend instrument useful lives and lower customer cost per use for benign outpatient, lower-reimbursement geographies. Rollout is described as progressive in 2027, with reassessment versus the 2020 program.
  • Capital environment and pipeline stability (US vs OUS): Management reported US capital environment stable, referencing Q2 US system placements +24% YoY and ~half of US systems under leasing (customer flexibility). They said international variability is driven by China pricing competition and Japan government funding, with distributor markets responding well to the segmented portfolio.

Sentiment: MIXED

Note: This summary was synthesized by AI from the ISRG Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — Intuitive Surgical, Inc. (ISRG) Financial Profile